Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.55, marking a +1.15% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.32%.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

Vertex Pharmaceuticals Inc. closed 9.68% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Review quarterly and annual revenue, net income, and cash flow for Vertex Pharmaceuticals Inc (VRTX:XNAS) stock through the last fiscal year.

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...